JP2005504829A5 - - Google Patents

Download PDF

Info

Publication number
JP2005504829A5
JP2005504829A5 JP2003532646A JP2003532646A JP2005504829A5 JP 2005504829 A5 JP2005504829 A5 JP 2005504829A5 JP 2003532646 A JP2003532646 A JP 2003532646A JP 2003532646 A JP2003532646 A JP 2003532646A JP 2005504829 A5 JP2005504829 A5 JP 2005504829A5
Authority
JP
Japan
Prior art keywords
peptide
inhibitor
seq
camkii
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003532646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/031496 external-priority patent/WO2003029428A2/en
Publication of JP2005504829A publication Critical patent/JP2005504829A/ja
Publication of JP2005504829A5 publication Critical patent/JP2005504829A5/ja
Pending legal-status Critical Current

Links

JP2003532646A 2001-10-01 2002-10-01 構造的心疾患における心筋機能不全を処置するためのカルモジュリンキナーゼiiインヒビターの使用 Pending JP2005504829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US32801001P 2001-10-08 2001-10-08
PCT/US2002/031496 WO2003029428A2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Publications (2)

Publication Number Publication Date
JP2005504829A JP2005504829A (ja) 2005-02-17
JP2005504829A5 true JP2005504829A5 (enExample) 2007-10-18

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003532646A Pending JP2005504829A (ja) 2001-10-01 2002-10-01 構造的心疾患における心筋機能不全を処置するためのカルモジュリンキナーゼiiインヒビターの使用

Country Status (14)

Country Link
US (2) US7320959B2 (enExample)
EP (1) EP1439849A4 (enExample)
JP (1) JP2005504829A (enExample)
KR (1) KR20040045041A (enExample)
CN (1) CN1599622A (enExample)
AU (1) AU2002341938B2 (enExample)
BR (1) BR0213043A (enExample)
CA (1) CA2462443A1 (enExample)
IL (1) IL161231A0 (enExample)
MX (1) MXPA04003040A (enExample)
NO (1) NO20041331L (enExample)
NZ (1) NZ532327A (enExample)
PL (1) PL369104A1 (enExample)
WO (1) WO2003029428A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1815867A4 (en) * 2004-11-02 2010-06-09 Dainippon Sumitomo Pharma Co COMBINED MEDICINE FOR THE TREATMENT OF AUTOIMMUNE DISEASE
JP5415520B2 (ja) * 2008-04-09 2014-02-12 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最大酸素消費量低下の予測のためのプロ−エンドセリン−1
US8841423B2 (en) 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
WO2010135676A1 (en) * 2009-05-22 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
US9951061B2 (en) 2013-03-06 2018-04-24 Allosteros Therapeutics, Inc. CaMKII inhibitors and uses thereof
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
CA2960101C (en) 2014-09-05 2024-05-21 Allosteros Therapeutics, Inc. Substituted carboline derivative and compositions thereof useful as camkii inhibitors
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
CN112972447B (zh) * 2021-03-02 2022-09-23 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) * 1968-10-17 1970-08-24
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0966274B1 (en) * 1997-01-31 2002-06-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
JP2963986B2 (ja) * 1997-11-19 1999-10-18 工業技術院長 カルモジュリン依存性リン酸化酵素iiの特異的阻害剤

Similar Documents

Publication Publication Date Title
KR101718639B1 (ko) 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
US20040209891A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
JP2005504829A5 (enExample)
JPH04226914A (ja) 狭心症治療用バクロフェン
US8664252B2 (en) Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US20080153827A1 (en) Method for the Treatment or Prevention of Cardiac Hypertrophy
CN1017150B (zh) 制备用作强心剂的杂环唑酮类的方法
CN86107814A (zh) 制备用作强心剂的噻唑酮的方法
JP2000513341A (ja) 血管拡張剤を使用する肝疾患および類似の徴候の治療法
JP2003277265A (ja) eNOS発現に起因する疾患の予防または治療薬
CN1181699A (zh) 用于治疗心血管疾病的氨基四氢化萘衍生物
Fauville et al. Severe diltiazem poisoning with intestinal pseudo-obstruction: case report and toxicological data
US9126989B2 (en) Compound and methods for treating long QT syndrome
JP4802470B2 (ja) 肝線維化抑制剤
ES2286595T3 (es) Combinacion de farmacos antidiabeticos.
NZ190028A (en) Pharmaceutical compositions containing a dibenzothiazepine
US20060142354A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
US20040023975A1 (en) Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome
CA2489545A1 (en) Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome
de Nooijer et al. The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction
JPWO2003020312A1 (ja) 虚血性心不全治療剤
Sawangkoon Potential for carvedilol to modify doxorubicin cardiotoxicity
JP2001172179A (ja) 多嚢胞性卵巣症候群治療剤
CN86107179A (zh) 用作强心剂的芳酰基噻唑酮的制备方法